Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds

Puricel, Serban; Arroyo, Diego; Corpataux, Noé; Baeriswyl, Gérard; Lehmann, Sonja; Kallinikou, Zacharenia; Müller, Olivier; Allard, Ludovic; Stauffer, Jean‐Christophe; Togni, Mario; Goy, Jean‐Jácques; Cook, Stéphane

doi:10.1016/j.jacc.2014.12.017

Cited by 193 publications

(136 citation statements)

References 31 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Results from available observational studies and randomized clinical trials are reassuring and very promising (16)(17)(18)(19)(20)(21)(22)(23). Rates of early BVS thrombosis in adverse anatomic scenarios, including the presence of a highly thrombogenic milieu, however, appear to be not negligible.…”

Section: Discussionmentioning

confidence: 99%

“…The EVERBIO II trial (22) randomized unselected "all-comers" patients, many of them presenting with an acute coronary syndrome (39% of patients but only 10% with STEMI), to BVS, EES or biolimus-DES. The primary endpoint of the study, the angiographic late lumen loss at 9-month follow-up, did not differ among the groups (0.28 mm in the BVS group, 0.25 mm in the DES groups).…”

Section: Attractiveness Of Bioresorbable Vascular Scaffolds (Bvs) In mentioning

confidence: 99%

See 1 more Smart Citation

Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?

Alfonso¹,

Cuesta²,

Bastante³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BVS) represent a disruptive technology that has caused a new revolution in interventional cardiology. BVS appear to be particularly appealing in patients presenting with an acute myocardial infarction (MI). The available evidence on the value of BVS implantation in this challenging scenario is very promising but still limited. Results come from preliminary small observational studies, prospective registries that include a control group, and from scarce randomized clinical trials with surrogate mechanistic or angiographic primary end-points. Further studies, powered for clinical endpoints, are required to establish the relative safety and efficacy of BVS vs. new-generation metallic drug-eluting stents (DES) in patients with ST-segment elevation acute MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Attractiveness Of Bioresorbable Vascular Scaffolds (Bvs) In mentioning

confidence: 99%

Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?

Alfonso¹,

Cuesta²,

Bastante³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…However, an increasing body of evidence from "real-life" registries reported concerning rates of stent thrombosis as high as 3% at 1 year (5-7). Although several randomised-controlled trials have shown equivalent safety and efficiency outcomes at mid-term between BVS and other newer generation DES (8)(9)(10), all were of relatively small size and underpowered to assess differences in clinically relevant but rare events such stent thrombosis. To date, 3 meta-analyses have assessed the performance of the device compared to metallic DES ( Table 1).…”

Section: From Excitement To Uncertaintymentioning

confidence: 99%

Bioresorbable vascular scaffolds—time to vanish?

2016

Self Cite

View full text Add to dashboard Cite

“…Randomized controlled trials (RCT) comparing a PLLA-BRS Absorb versus a cobalt chromium everolimuseluting stent have shown slightly but non significantly worse outcomes of PLLA-BRS at 1 year, but progressively unfavorable outcomes have surfaced up to 3 years (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24).…”

Section: Introductionmentioning

confidence: 99%

Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives

Rapetto¹,

Leoncini²

2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best option for percutaneous coronary interventions (PCI) based revascularization. However, despite their optimal performance, a few concerns remain regarding their use, mainly due to permanent caging of the vessels and its consequences, first of all late stent thrombosis (ST). Bioresorbable scaffolds (BRS) aim to overcome these issues. The results achieved in randomized controlled trials (RCT) by the first generation of poly-L-lactic acid (PLLA) based scaffolds were promising at 1 year, but the first long term reports (albeit flawed by nonoptimal implantation technique) have been disappointing, showing, for instance, an increased risk of ST and target vessel myocardial infarction (TV-MI). In such a scenario the advent of a newer generation magnesium (Mg) based BRS is welcome, mainly because of its innovative mechanical and chemical features coupled with well proven biocompatibility. Despite being in its infancy, this technology seems to promise a great potential.In our article, we review the Magmaris (Biotronik AG, Bülach, Switzerland) Mg BRS development from animal models to human use, underscore its best qualities and weaknesses, and provide hints of its possible future perspectives.

show abstract

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds

Abstract: New-generation metallic DES (EES/BES) were not superior to BVS in terms of angiographic LLL and clinical outcomes. (Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents [EVERBIO II]; NCT01711931).

Cited by 193 publications

References 31 publications

Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?

Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?

Bioresorbable vascular scaffolds—time to vanish?

Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives

Contact Info

Product

Resources

About